SEVOflurane Inhalation in CARdiac Arrest Resuscitated Patients Treated With Therapeutic Hypothermia (SEVOCAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02201134|
Recruitment Status : Unknown
Verified July 2016 by University Hospital, Clermont-Ferrand.
Recruitment status was: Recruiting
First Posted : July 25, 2014
Last Update Posted : July 29, 2016
|Condition or disease||Intervention/treatment||Phase|
|Cardiac Arrest Therapeutic Hypothermia||Drug: sevoflurane||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||SEVOflurane Inhalation in CARdiac Arrest Resuscitated Patients Treated With Therapeutic Hypothermia|
|Study Start Date :||July 2014|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2016|
- Determination of the feasibility of a sedation with inhalated sevoflurane in cardiac arrest resuscitated patients [ Time Frame: at day 1 ]The feasibility is evaluated by the number of side effects due to treatment until discharge from hospital.
- Determination of neurological prognostic of patients at ICU and hospital discharge [ Time Frame: at day 1 ]
- Determination of systemic complications and organ failures during hospitalisation [ Time Frame: at day 1 ]
- Evaluation of systemic inflammation and evolution with cytokines [ Time Frame: at day 1 ]
- Evaluation of markers specific of brain ischemia (S100 protein and neuron-specific enolase) [ Time Frame: at day 1 ]at 3 times: before starting sevoflurane sedation, 24 hours, 48 hours and 72 hours after starting sevoflurane sedation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02201134
|Contact: Patrick LACARIN||04 73 75 11 email@example.com|
|CHU de Clermont-Ferrand||Recruiting|
|Clermont-Ferrand, France, 63003|
|Contact: Patrick LACARIN 04 73 75 11 95 firstname.lastname@example.org|
|Principal Investigator:||Sébastien PERBET||University Hospital, Clermont-Ferrand|